H.I.G. BioHealth closes $220 mln HyperBranch Medical sale

H.I.G. BioHealth Partners, the healthcare investment affiliate of H.I.G. Capital, said Oct. 11 that closed the sale of it HyperBranch Medical Technology Inc to Stryker Corp for about $220 million. HyperBranch develops medical devices. Cooley LLP represented HyperBranch in the transaction.

DealsNorth AmericaUSHealthcareBriefs